<DOC>
	<DOCNO>NCT01737853</DOCNO>
	<brief_summary>The objective phase IV clinical multi-center trial compare efficacy safety Ganforti® versus Krytantek® , use cross-over design six month period ( include one-month wash-in period ) POAG OH patient .</brief_summary>
	<brief_title>Comparison Efficacy &amp; Tolerability Between Ganfort v Krytantek Mexican Patients With Primary Open-Angle Glaucoma ( POAG ) Ocular Hypertension ( OHT )</brief_title>
	<detailed_description>A prospective examiner-masked , cross-over competitive multicenter clinical trial 90 consecutive patient derive three center Mexico carry . All eligible eye diagnosis either ocular hypertension mild moderate POAG least 21 mm Hg baseline ( Eligibility Visit ) , treatment either Ganforti® QD Krytantek® BID . Patients identified selection criterion Screening Visit schedule Eligibility Visit prior prescribe either two study medication ( Ganforti® QD patient Krytantek® , Krytantek® BID patient Ganforti® ) . Enrolled patient visit clinical site month 2 month 3 , start study medication ; end third month treatment , cross-over maneuver indicate ; patient undergo follow-up scheme similar first period study ( month 5 month 6 ) . A battery test apply pre-established regime ( table 1 ) . Visual acuity , refraction , biomicroscopy , gonioscopy , dilate fundus examination , Humphrey 24-2 visual field ( SITA-Standard ) , ocular surface fluorescein staining , tear breakup time , OSDI© ( Ocular Surface Index ) central ultrasound pachymetry administer baseline month 6 ( conclusion study ) . IOP applanation Goldmann tonometry ( 8:00 AM ± 1 hour 10:00 AM ± 1 hour ) , blood pressure , pulse comprehensive ophthalmological examination perform visit . Candidate patient initial screen visit entry criterion must meet ( see section 1.7. ) . Study medication remain mask examiner entire trial . For patient assign Ganforti 's group , instruction apply one drop QD ( 8:00 PM ± 30 minute ) ; patient assign Krytantek 's group , application schedule BID ( 8:00 AM ± 30 minute 8:00 PM ± 30 minute ) . Bottles give patient close label box ( randomization number ) , dispensed office assistant , return box assign office personnel never principal investigator sub-investigator , order preserve single-masked nature study . New study medication bottle dispense baseline visit , monthly visit . Patients receive verbal instruction , write reminder periodic phone call order adhere medication application , well schedule visit ( table 1 ) . Outcome variable also include adverse event ( serious , non-serious , accord principal investigator 's clinical opinion ) derive examination item . Patient´s treat ophthalmologist´s subjective satisfaction study medication performance also assess closed-end question ( CRF form ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Cloprostenol</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Bestcorrected visual acuity least 20/80 eye Age 17 year Use active contraceptive method woman reproductive phase life Complete demographic baseline information ( Eligibility Visit ) IOP ≥ 18 mm Hg ≤ 36 mm Hg Significant visual field loss previous year Uncontrolled systemic disease Active ocular disease intraocular surgery within past three month Use medication possible substantial effect IOP Allergy/contraindication study component Severe glaucoma accord Hodapp 's criterion Incapacity unwillingness participate study Any ocular illness mildmoderate lens loss transparency glaucoma/ocular hypertension</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Primary Open-Angle Glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
	<keyword>Ganfort</keyword>
</DOC>